In addition, the combination of an ACE inhibitor with an ARB or with a direct renin inhibitor in two other large trials of patients with diabetic chronic kidney disease (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints [ALTITUDE] and Veterans Affairs Nephropathy in Diabetes [VA NEPHRON-D]) was not superior to ACE inhibitor monotherapy and produced more side effects.